Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARIFY: 64Cu-SAR-bisPSMA PET in High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830Phase 3Recruiting
- Sponsor
- Clarity Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 3
01
Overview
A Phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer (PCa), sponsored by Clarity Pharmaceuticals. Started Dec 2023; status: recruiting.
02
Drugs
64Cu-SAR-bisPSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06056830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056830.